4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunic, Inc. (IMUX) operates in the Biotechnology industry and is headquartered in New York, United States with about 95 employees. Its market capitalization is roughly $202 million. In the fiscal year ended 2025-12-31, IMUX reported $0M in revenue and ($97M) in net income.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($103M) | ($98M) | ($99M) | ($86M) | — |
| Net Income | ($97M) | ($100M) | ($94M) | ($120M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($33M) | ($23M) | ($26M) | ($27M) | ($27M) | — |
| Net Income | ($33M) | ($19M) | ($26M) | ($27M) | ($26M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $24M | $41M | $54M | $128M | — |
| Total Liabilities | $31M | $22M | $25M | $14M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMUX viewer.
About TickerBase · Data methodology & sources